Bristol Myers' Iza-bren Shows Dual PFS and OS Benefit in Phase 3 TNBC Trial
Bristol Myers reported positive interim Phase 3 results for izalontamab brengitecan in unresectable triple-negative breast cancer, meeting dual primary endpoints of progression-free survival and overall survival. The antibody-drug conjugate holds Breakthrough Therapy Designation from the U.S. FDA and China’s National Medical Products Administration, marking its third Phase 3 success.
1. Phase 3 Trial Success
In a Phase 3 study of izalontamab brengitecan, patients with unresectable locally advanced or metastatic triple-negative breast cancer previously treated with taxanes achieved statistically significant improvements in both progression-free survival and overall survival compared with standard chemotherapy.
2. Regulatory Breakthroughs
Iza-bren has been granted Breakthrough Therapy Designation by the U.S. FDA and China’s National Medical Products Administration for multiple indications, which could accelerate review and potential approval pathways for this therapy in aggressive breast cancer populations.
3. Stock and Technical Reaction
Shares of Bristol Myers dipped 0.56% to $60.95, trading below their 20-day and 100-day simple moving averages. Technical indicators show neutral RSI and bearish MACD, with key support at $60.00 and resistance at $63.00.
4. Analyst Outlook
The consensus Hold rating carries an average price target of $60.09, while RBC initiated Sector Perform at $60. Piper Sandler and Barclays have set Overweight ratings with $75 targets, reflecting confidence in Iza-bren’s revenue potential upon approval.